Figure 4. Reversion of the deficient formation of BRCA1 and FANCD2 foci in BCR/ABL-transduced cord blood CD34⁺ cells by inhibitors of the proteasome and the PI3K/Akt pathway.

Experimental protocol and analysis of the proportion of MIN-R1 and MIN-210-transduced cord blood CD34⁺ cells with BRCA1 (white bars) or FANCD2 foci (black bars) after treatment with the proteasome inhibitor MG132, or the PI3K/AKT inhibitor Ly294002. Bars show mean ± s.e. of values corresponding to three independent experiments. *Differences were significant at p<0.01.